Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 229 for your search:
Cancer Type:
Lymphoma, Hodgkin lymphoma, adult
Stage/Subtype of Cancer:
recurrent adult Hodgkin lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Other
Protocol IDs:
MCC-14178
, NCT00361140
2.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 55
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GC P#02.01.001
, NCT00469729
3.
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
4.
Total-Body Irradiation With Or Without Fludarabine Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1813.00
, 5666, NCT00075478
5.
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
NCI
Protocol IDs:
CBMTG-0601
, NCT00438958
6.
Biological Therapy in Treating Patients With Lymphoma or Lymphoproliferative Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MSKCC-95024
, NCI-V95-0685, NCT00002663
7.
Radiolabeled Monoclonal Antibody Therapy in Treating Adult Patients Who Have Recurrent Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-97-C-0110
, NCT00019305
8.
Peripheral Stem Transplantation in Treating Patients With Refractory or Relapsed Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1409.00
, 4903, NCI-G00-1776, NCT00005803
9.
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-1803.00
, 5606, NCT00068718
10.
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
H8713
, NCT00058825
11.
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
OSU-04100
, OSU-2005C0006, NCI-7002, 7002, NCT00112723
12.
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J0528
, NCT00134082
13.
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-05011-L
, OHSU-210, NCT00245037
14.
Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Older patients
Sponsor:
NCI, Other
Protocol IDs:
BMT124
, 75117, BMT124, NCT00185692, NCT00185692
15.
A Study of SB-743921 in Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CY 2121
, NCT00343564
16.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-065
, X05175, NCT00369226
17.
ABT-263 in Treating Patients With Relapsed or Refractory Lymphoid Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0006
, NCI-P7060, ABBOTT-M06-814, NCT00408811
18.
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
2006-0803
, NCT00410982
19.
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
04U.115
, NCT00429416
20.
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
TNX-650.101
, NCT00441818
21.
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-LS0689
, LS0689, MAYO-07-000710, NCT00474929
22.
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PDX-009
, NCT00481871
23.
Post-Transplant Autologous Cytokine-Induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
BMT173
, 95889, BMT173, NCT00477035, NCT00477035
24.
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
J0703
, NA00005743, NCT00484874
25.
Chemotherapy, Donor Stem Cell Transplant, and Graft-Versus-Host Disease Prevention in Treating Patients With Advanced Hematologic Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0195
, 07-C-0195, NCT00520130
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
